Zacks Investment Research
12 Aug 2026, 15:51 UTC · 1h ago
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
12 Aug 2026, 15:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Vopimetostat, Tango's lead candidate, showed a 92% objective response rate in a phase I/II study for MTAP-deleted, RAS-mutant pancreatic cancer. — Strong clinical efficacy for a lead pipeline candidate is the primary long-term value driver for biotech firms.
+0.50Tango Therapeutics reported Q2 2026 loss per share of 37 cents, missing the Zacks Consensus Estimate of 31 cents. — An earnings miss typically triggers immediate negative price action, as seen in the stock's 4.8% decline.
-0.40Collaboration revenues fell to zero in Q2 2026 from $3.2 million in the prior year following the truncation of the Gilead collaboration agreement. — The loss of a major collaboration partner removes a source of non-dilutive funding for a company with no marketed products.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
General and administrative expenses nearly doubled year-over-year to $22.6 million, driven primarily by personnel costs and share-based compensation. — Rapidly increasing overhead without corresponding revenue growth accelerates cash burn.
-0.20Which stocks this story touches
The company reported an earnings miss with wider-than-expected losses and zero collaboration revenues, leading to a share price drop.
[mutual] Tango Therapeutics had a collaboration agreement with Gilead that concluded all research activities.
[mutual] Tango Therapeutics conducted a phase I/II study evaluating its lead candidate in combination with Revolution Medicines' inhibitors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
See It Market
2h ago
